Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174177 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173095 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL537432 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173886 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173917 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173350 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2175508 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL423932 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL2173923 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA | |
| SCHEMBL1824570 | 1.00 | FFAR1 (0.31) | FFAR1CPT2TDP1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973145-B2 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | FFAR1 17/4885CPT2 34/4885TDP1 4440/4885 |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | FFAR1 17/4885CPT2 34/4885TDP1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.